title: Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate.
abstract: BACKGROUND
  Washing out of thawed autologous grafts, before reinfusion in poor-prognosis cancer patients who undergo high-dose chemotherapy, is desirable. The procedure allows for the reduction of infused dimethyl sulfoxide (DMSO) quantities and the performance of biologic controls on the infused cell product.
  
  
  METHODS
  Three-hundred four patients were treated with intensified chemotherapy and autologous transplantation at a single institution. Fifty-four of them received washed cell products, because three or more bags were to be reinfused. The recently available, closed, automated, and current good manufacturing practice-compliant device (CytoMate, Baxter Oncology) was used for this purpose.
  
  
  RESULTS
  The performances of the device were similar to previously reported results, with greater than 75 percent CD34+ cell recovery. Neutrophil and platelet (PLT) recoveries were similar in the group of patients receiving washed cells and in the group of patients for whom cell products were extemporaneously thawed at the bedside. Adverse events that are typically reported after DMSO infusion were significantly less frequent and less severe in patients who received washed cells. Finally, the nurse staff on the transplant ward reported a decreased workload and more satisfactory procedure when infusing washed cell products.
  
  
  CONCLUSIONS
  The CytoMate device allows for a significant reduction in DMSO infusion, with a diminished frequency and severity of immediate side effects and does not compromise neutrophil or PLT engraftment.
authors.affiliation: Center of Cellular and Genetic Therapy, Department of Oncohematology, Transplantation and Cellular Therapy Unit, Paoli-Calmettes Institute, Marseille, France. lemariec@marseille.fnclcc.fr
authors.forename: Claude
authors.initials: C
authors.lastname: Lemarie
authors.forename: Boris
authors.initials: B
authors.lastname: Calmels
authors.forename: Carine
authors.initials: C
authors.lastname: Malenfant
authors.forename: Vérane
authors.initials: V
authors.lastname: Arneodo
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Frédéric
authors.initials: F
authors.lastname: Viret
authors.forename: Réda
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: Patrick
authors.initials: P
authors.lastname: Ladaique
authors.forename: Patrice
authors.initials: P
authors.lastname: Viens
authors.forename: Christian
authors.initials: C
authors.lastname: Chabannon
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001781:Blood Component Removal / Q000295:instrumentation*; D001804:Blood Transfusion, Autologous / Q000009:adverse effects / Q000295:instrumentation*; D003131:Combined Modality Therapy; D015925:Cryopreservation / Q000295:instrumentation*; D003451:Cryoprotective Agents / Q000009:adverse effects; D004121:Dimethyl Sulfoxide / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000295:instrumentation*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D003451:Cryoprotective Agents; D004121:Dimethyl Sulfoxide